(-)-Blebbistatin: Precision Non-Muscle Myosin II Inhibitor for Cytoskeletal Dynamics Research

Executive Summary: (-)-Blebbistatin (CAS 856925-71-8) is a highly selective, cell-permeable inhibitor of non-muscle myosin II (NM II), enabling reversible, dose-dependent suppression of actomyosin contractility (APExBIO, product page). The compound binds the myosin-ADP-phosphate complex and slows phosphate release, with an IC50 of 0.5–5.0 μM for NM II and minimal off-target activity. Peer-reviewed studies confirm its utility in dissecting mechanotransduction—such as blocking stress-induced YAP nuclear translocation, implicating actomyosin contractility in cellular mechanomemory (Rashid et al., 2025). (-)-Blebbistatin's unique solubility (DMSO only) and storage requirements (-20°C as solid) are critical for reproducibility. Its applications span cell migration, adhesion, cardiac contractility, and advanced disease modeling, but efficacy is limited in systems dominated by smooth muscle or unconventional myosins.

Biological Rationale

Non-muscle myosin II (NM II) is a pivotal actin-dependent motor protein governing cell shape, migration, and adhesion. Many cell processes—including cytokinesis, mechanotransduction, and morphogenesis—require finely tuned NM II activity. Disruptions in NM II function underlie numerous pathological states, ranging from impaired wound healing to tumor progression and MYH9-related diseases. (-)-Blebbistatin addresses the need for a selective, reversible tool to dissect NM II-specific pathways, enabling temporal control over actomyosin contractility without broadly affecting other myosins or cytoskeletal elements (APExBIO).

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin specifically binds to the myosin-ADP-phosphate complex within NM II, stabilizing it in a state that reduces phosphate release and suppresses Mg-ATPase activity. This leads to reversible inhibition of actin-myosin interactions and contractility. The compound demonstrates nanomolar to low micromolar potency (IC50: 0.5–5.0 μM for NM II), with greatly reduced activity toward smooth muscle myosin II (IC50 ~80 μM) and negligible effects on myosin I, V, and X isoforms, ensuring functional selectivity (Rashid et al., 2025). The inhibition is cell-permeable, allowing application in live-cell assays and animal models. Importantly, the effect is reversible: washing out (-)-blebbistatin restores myosin II activity, facilitating kinetic studies and temporal perturbations. The compound is insoluble in water and ethanol, but dissolves in DMSO up to ≥14.62 mg/mL, dictating formulation strategies for experimental use (APExBIO).

Evidence & Benchmarks

• (-)-Blebbistatin at 5 μM reversibly blocks actomyosin-dependent YAP nuclear translocation in response to intermittent mechanical stress, elucidating the role of actomyosin contractility in mechanomemory (Rashid et al., 2025, https://doi.org/10.1063/5.0253046).
• The compound exhibits an IC50 range of 0.5–5.0 μM for NM II ATPase inhibition in cell-based and biochemical assays (APExBIO, product page).
• Minimal activity is observed against myosin I, V, and X isoforms, and the IC50 for smooth muscle myosin II is approximately 80 μM, supporting high selectivity (APExBIO, product page).
• In zebrafish embryos, (-)-Blebbistatin induces dose-dependent cardia bifida, demonstrating utility in developmental models (APExBIO, product page).
• Stock solutions in DMSO remain stable for several months at ≤-20°C, but aqueous solutions degrade rapidly, necessitating prompt use (APExBIO, product page).

This article extends the scope of "(-)-Blebbistatin: Transforming Cytoskeletal Dynamics Research" by providing updated mechanistic context from 2025 peer-reviewed studies on mechanomemory and YAP signaling. It also clarifies the limits and practicalities highlighted in "(-)-Blebbistatin (SKU B1387): Optimizing Cytoskeletal Dynamics" by explicitly discussing solubility, storage, and off-target boundaries. For a workflow troubleshooting perspective, see "Overcoming Cytoskeletal Assay Challenges with (-)-Blebbistatin".

Applications, Limits & Misconceptions

Key applications of (-)-Blebbistatin include:

• Dissecting actin-myosin interactions and contractility in live cells and tissues.
• Studying cell adhesion, migration, and mechanotransduction, including YAP/TAZ signaling cascades.
• Modulating cardiac muscle contractility and calcium wave propagation in animal models.
• Modeling MYH9-related disease phenotypes and probing tumor cell mechanics.
• Facilitating reproducible, temporal inhibition in cytoskeletal and cell mechanics research.

Limits and boundaries:

• Reduced efficacy in systems dominated by smooth muscle myosin II or unconventional myosins (e.g., myosin I, V, X).
• Not suitable for applications requiring aqueous solubility or compatibility with ethanol-based protocols.
• Photoinstability and rapid degradation in aqueous solution limit use in long-term or light-exposed experiments (APExBIO).

Common Pitfalls or Misconceptions

• Misconception: (-)-Blebbistatin inhibits all myosin isoforms. Fact: It is selective for non-muscle myosin II, with minimal effect on myosin I, V, X, or smooth muscle myosin II at standard concentrations.
• Misconception: It is water soluble. Fact: (-)-Blebbistatin is only soluble in DMSO at ≥14.62 mg/mL and is insoluble in water or ethanol.
• Pitfall: Preparing and storing solutions at room temperature leads to rapid degradation; always store solid at -20°C and use solutions immediately.
• Pitfall: Prolonged light exposure degrades (-)-Blebbistatin. Protect from light during preparation and experiments.
• Boundary: Inhibition is reversible; do not expect permanent cytoskeletal changes post-washout.

Workflow Integration & Parameters

For best results, prepare stock solutions in anhydrous DMSO at concentrations up to 14.62 mg/mL. Warm gently and sonicate if necessary to achieve full dissolution. Store solid stocks at -20°C; DMSO solutions can be aliquoted and stored at ≤-20°C for up to several months if protected from light. For cell-based assays, dilute DMSO stocks directly into culture media to final concentrations of 0.5–10 μM, ensuring that the final DMSO concentration does not exceed 0.5% (v/v) to avoid cytotoxicity (APExBIO). For in vivo work (e.g., zebrafish embryos), titrate the dose carefully to observe dose-dependent phenotypes such as cardia bifida. Washout protocols enable reversible inhibition, supporting kinetic and recovery studies. Always use freshly prepared working solutions and perform controls for vehicle and light exposure.

Conclusion & Outlook

(-)-Blebbistatin, supplied by APExBIO, is a rigorously validated, reversible, and highly selective non-muscle myosin II inhibitor. Its precision makes it indispensable for dissecting cytoskeletal mechanics, mechanotransduction, and related disease models. Recent evidence underscores its unique role in clarifying the molecular basis of mechanomemory and YAP signaling. Users must adhere to strict solubility and storage guidelines to maintain activity and experimental fidelity. Future developments may expand its use in complex tissue models and integrated mechanobiology platforms, while highlighting the ongoing need for isoform-specific, reversible inhibitors in cell and developmental biology.